PURPOSE: The aim of this study was to describe the use of palliative sedation (PS) its indications and outcomes in patients followed up till death by an inpatient palliative care consult team (PCCT) at a tertiary cancer center. METHODS: All patients referred for 5 years to the PCCT and followed up till death were eligible for the study. Both PCCT recordings and hospital charts were reviewed and a codified assessment was performed. RESULTS: Over a total of 2,033 consecutive consults, 129 patients died during admission and were eligible. Eighty-three had the indication to PS, 4% of all consults (95% confidence interval [95%CI], 3% to 5%) and 64% of eligible patients (95%CI, 56% to 73%). PS was more frequently indicated in males and in patients with recurrent dyspnea and recurrent agitation, while it was less frequently indicated in older people and in patients with cerebral metastases and recurrent drowsiness. The most frequent indications to PS were dyspnea (37%) and delirium (31%) alone or combined with other symptoms. PS was successfully achieved in 69 patients; the drugs most frequently used for PS were midazolam (46%), haloperidol (35%), and chlorpromazine (32%) and opioid dose escalation was higher in sedated patients (P < 0.01). CONCLUSIONS: PS is an important intervention in the management of terminal disease by a consulting palliative care team. Improved collaboration and communication between the hospital staff and the PCCT should be offered to meet patients' needs when PS is required.
PURPOSE: The aim of this study was to describe the use of palliative sedation (PS) its indications and outcomes in patients followed up till death by an inpatient palliative care consult team (PCCT) at a tertiary cancer center. METHODS: All patients referred for 5 years to the PCCT and followed up till death were eligible for the study. Both PCCT recordings and hospital charts were reviewed and a codified assessment was performed. RESULTS: Over a total of 2,033 consecutive consults, 129 patients died during admission and were eligible. Eighty-three had the indication to PS, 4% of all consults (95% confidence interval [95%CI], 3% to 5%) and 64% of eligible patients (95%CI, 56% to 73%). PS was more frequently indicated in males and in patients with recurrent dyspnea and recurrent agitation, while it was less frequently indicated in older people and in patients with cerebral metastases and recurrent drowsiness. The most frequent indications to PS were dyspnea (37%) and delirium (31%) alone or combined with other symptoms. PS was successfully achieved in 69 patients; the drugs most frequently used for PS were midazolam (46%), haloperidol (35%), and chlorpromazine (32%) and opioid dose escalation was higher in sedated patients (P < 0.01). CONCLUSIONS:PS is an important intervention in the management of terminal disease by a consulting palliative care team. Improved collaboration and communication between the hospital staff and the PCCT should be offered to meet patients' needs when PS is required.
Authors: A Caraceni; O Nanni; M Maltoni; L Piva; M Indelli; E Arnoldi; M Monti; L Montanari; D Amadori; F De Conno Journal: Cancer Date: 2000-09-01 Impact factor: 6.860
Authors: M Maltoni; C Pittureri; E Scarpi; L Piccinini; F Martini; P Turci; L Montanari; O Nanni; D Amadori Journal: Ann Oncol Date: 2009-07 Impact factor: 32.976
Authors: C Peruselli; P Di Giulio; F Toscani; M Gallucci; C Brunelli; M Costantini; M Tamburini; E Paci; G Miccinesi; J M Addington-Hall; I J Higginson Journal: Palliat Med Date: 1999-05 Impact factor: 4.762
Authors: Philipp R Klosa; Carsten Klein; Maria Heckel; Alexandra C Bronnhuber; Christoph Ostgathe; Stephanie Stiel Journal: Support Care Cancer Date: 2014-04-18 Impact factor: 3.603
Authors: Stephanie Stiel; Maria Heckel; Britta Christensen; Christoph Ostgathe; Carsten Klein Journal: Support Care Cancer Date: 2015-08-14 Impact factor: 3.603
Authors: Santiago Parra Palacio; Clara Elisa Giraldo Hoyos; Camilo Arias Rodríguez; Daniel Mejía Arrieta; John Jairo Vargas Gómez; Alicia Krikorian Journal: Support Care Cancer Date: 2018-03-29 Impact factor: 3.603
Authors: Ebun Abarshi; Judith Rietjens; Augusto Caraceni; Sheila Payne; Luc Deliens; Lieve Van Den Block Journal: BMC Palliat Care Date: 2014-07-07 Impact factor: 3.234
Authors: Yoonyoung Park; Brian T Bateman; Dae Hyun Kim; Sonia Hernandez-Diaz; Elisabetta Patorno; Robert J Glynn; Helen Mogun; Krista F Huybrechts Journal: BMJ Date: 2018-03-28